Trial Type: Head and Neck Cancer

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications. (ABBV-400 is an antibody drug conjugate targeting c-Met with a topoisomerase 1 (Top1) inhibitor payload.)

A Phase 3 Multicenter, Randomized, Double-arm, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases

Head and Neck Cancer study project in the Geriatric Population

First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors

This drug causes immune activation by blocking PTPN2/N1. The study drug is given alone and in combination with PD-1 inhibitors. Cohorts in kidney cancer, head and neck, and other solid tumors.

Bifunctional antibody against EGFR and TGF Beta, alone and in combination with pembrolizumab for Head and neck cancer, NSCLC and anal cancer and cutaneous squamous cell cancer